AI-powered search

2024 Virtual Grand Rounds

2024 Virtual Grand Rounds Session 14: November 6, 2024 - Highlights from Fall Clinical 2024: Your Questions Answered

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, November 6, 2024

8 PM ET / 5 PM PT

Highlights from Fall Clinical 2024: Your Questions Answered

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

November 7, 2024

Expiration Date:

November 7, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Discuss the pathogenesis and optimal management of psoriasis, atopic dermatitis and acne vulgaris

  • Update knowledge regarding recent advances in the safe and effective use of biologic agents for the treatment of dermatologic diseases

  • Enhance the ability to evaluate and incorporate new techniques and uses of dermal fillers and neurotoxins

  • Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents approved for use in the dermatology setting Integrate prevention, diagnosis, and management of skin cancer into my clinical setting

  • Diagnose commonly presented dermatologic disorders

  • Improve my clinical interactions with patients

  • Integrate knowledge to enhance daily dermatologic care

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Faculty
Andrew
Andrew Alexis, MD, MPH

Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology 
Weill Cornell Medicine
New York, NY

April
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Alexandra
Alexandra Golant, MD

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Mark
Mark Nestor, MD, PhD

Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL

Darrell
Darrell Rigel, MS, MD

Clinical Professor of Dermatology 
New York University
Grossman School of Medicine
New York, NY 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Andrew F. Alexis, MD, MPH

Grant/Research Support: BMS, LEO, Novartis, Almirall

Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron

Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS

April W. Armstrong, MD, MPH

Advisory Board/Consultant: ASLAN, Almirall, Amgen, Arcutis, Beiersdorf, BMS, Dermavant, EPI
Health, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, SUN Pharma, Takeda, Ventyx Biosciences

Board Member: Board of Director Elect, American Academy of Dermatology

Grant/Research Support: Abbvie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli
Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Seika Pharma Co, Modernizing Medicine, Nimbus Therapeautics, Novartis, Ortho Dermatologics,
Pfizer, Sanofi, Genzyme, UCB, Ventyx Biosciences

Speakers Bureau: Abbvie, Amgen, BMS, Janssen, Mindera, Organon & Co, Sanofi, Takeda

Other Relationships: Data Safety Monitoring Board: Boehringer Ingelheim, Parexel

Alexandra K. Golant, MD

Advisory Board: Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi

Consultant: Abbvie, Arcutis, Dermavant, Galderma, Lilly, Regeneron, Sanofi

Speakers’ Bureau Honoraria: Abbvie, Arcutis, Dermavant, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio Biosciences, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc.
Consultant: Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb,  Castle Biosciences, Celltrion,  Corevitas, Dermavant Sciences,  EPI, Evommune, Inc., Facilitation of  International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology,  Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron,  Seanergy, Strata, Takeda,Trevi, and Verrica

Mark S. Nestor, MD, PhD

Advisory Board: Algeness, AMP Biologics, Castle Biosciences, Eirion Therapeutics Inc., Ferndale, Galderma, HTL Research, Hugel America, Ipsen, Novaestiq Corp, Primus Pharmaceuticals, RVL Pharmaceuticals, Sensus Healthcare, Sirnaomics

Grant/Research Support: Castle Biosciences, CROMA Pharma GmbH, Dermata Therapeutics, Eirion Therapeutics Inc., Fudan-Zhangjiang Co. Ltd., Galderma, Incyte corp., Jetema Co., Krystal Biotech, Mediwound, Merz Pharma, Mino Labs, Sirnaomics, Suneval Medical, Sun Pharma, Veradermics Inc.

Consultant: Aerolase, AMP Biologics, Benev Co. Inc., CROMA Pharma GmbH, Dermsquared, Eirion Therapeutics Inc., Emblation / Sarosa, HTL Research, Ipsen, Mediwound, Novaestiq Corp, Primus Pharmaceuticals, Revian, Sensus Healthcare, Sirnaomics, Sofwave, Vial

Speakers/ Bureau or Honoraria: Sensus Healthcare

Darrell S. Rigel, MS, MD

Advisory Board: Castle Biosciences, Almirall

Grant/Research Support: Castle Biosciences

Consultant: Castle Biosciences

Speakers’ Bureau Honoraria: Beiersdorf, Castle Biosciences, Almirall, DermTech

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved